Azenta, Inc. (AZTA) vs Mineralys Therapeutics, Inc. (MLYS)
A side-by-side comparison of Azenta, Inc. and Mineralys Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AZTA
Azenta, Inc.
$40.26HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
MLYS
Mineralys Therapeutics, Inc.
$22.18HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
Total return — AZTA vs MLYS
growth of $100 · dividends reinvested · last 4yAZTA -26.5% (-7.4%/yr)MLYS +26.4% (+6.0%/yr)MLYS compounded faster over this window
AZTA MLYS
AZTA vs MLYS: by the numbers
- •MLYS is the larger company ($1.96B vs $1.86B market cap).
- •Both run net losses; MLYS's is the smaller (0.00% vs -20.02% net margin).
Metrics side by side
Valuation
| Metric | AZTA | MLYS |
|---|---|---|
| Forward P/E | 81.06 | N/A |
| P/S ratio | 3.02 | N/A |
| P/B ratio | 1.23 | 3.55 |
| EV / EBITDA | 50.24 | N/A |
| FCF yield | 0.53% | N/A |
Profitability
| Metric | AZTA | MLYS |
|---|---|---|
| Gross margin | 44.05% | 0.00% |
| Operating margin | -3.49% | 0.00% |
| Net margin | -20.02% | 0.00% |
| ROE | -8.14% | -63.45% |
| ROIC | -1.33% | -57.17% |
Growth (annualized)
| Metric | AZTA | MLYS |
|---|---|---|
| Revenue CAGR (5Y) | 4.82% | N/A |
| Total return CAGR (5Y) | -15.91% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.